{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:32:25Z","timestamp":1785616345753,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11606-021-06634-7","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T15:17:43Z","timestamp":1612797463000},"page":"1380-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8256","authenticated-orcid":false,"given":"Sean J.","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Grimstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Irwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol S.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"6634_CR1","unstructured":"Flores AR, Herman JL, Gates GJ, Brown TNT. How many adults identify as transgender in the United States? 2016. https:\/\/williamsinstitute.law.ucla.edu\/wp-content\/uploads\/How-Many-Adults-Identify-as-Transgender-in-the-United-States.pdf. Accessed 6\/17\/2020."},{"key":"6634_CR2","unstructured":"James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey. National Center for Transgender Equality, Washington, DC, 2016, Washington, DC. 2016. https:\/\/transequality.org\/sites\/default\/files\/docs\/usts\/USTS-Full-Report-Dec17.pdf. Accessed 6\/17\/2020."},{"issue":"6","key":"6634_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1370\/afm.2298","volume":"16","author":"DA Shires","year":"2018","unstructured":"Shires DA, Stroumsa D, Jaffee KD, Woodford MR. Primary Care Clinicians' Willingness to Care for Transgender Patients. Ann Fam Med. 2018;16(6):555-8. doi:https:\/\/doi.org\/10.1370\/afm.2298","journal-title":"Ann Fam Med."},{"key":"6634_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/15532739.2011.700873","volume":"13","author":"E Coleman","year":"2012","unstructured":"Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13:165-232.","journal-title":"Int J Transgenderism."},{"key":"6634_CR5","unstructured":"World Health Organization, Cardiovascular Diseases https:\/\/www.who.int\/health-topics\/cardiovascular-diseases\/#tab=tab_1. Accessed 6\/17\/2020."},{"key":"6634_CR6","doi-asserted-by":"publisher","unstructured":"Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017;102(11):3914\u201323. https:\/\/doi.org\/10.1210\/jc.2017-01643","DOI":"10.1210\/jc.2017-01643"},{"key":"6634_CR7","doi-asserted-by":"publisher","unstructured":"Streed CG, Jr., Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med. 2017;167(4):256\u201367. https:\/\/doi.org\/10.7326\/m17-0577","DOI":"10.7326\/m17-0577"},{"issue":"2","key":"6634_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10865-019-00102-8","volume":"43","author":"BA Caceres","year":"2020","unstructured":"Caceres BA, Jackman KB, Edmondson D, Bockting WO. Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS. J Behav Med. 2020;43(2):329\u201338. doi:https:\/\/doi.org\/10.1007\/s10865-019-00102-8","journal-title":"J Behav Med."},{"key":"6634_CR9","doi-asserted-by":"publisher","unstructured":"Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005597. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005597","DOI":"10.1161\/CIRCOUTCOMES.119.005597"},{"key":"6634_CR10","doi-asserted-by":"publisher","unstructured":"Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann Intern Med. 2018;169(4):205-13. https:\/\/doi.org\/10.7326\/M17-2785","DOI":"10.7326\/M17-2785"},{"key":"6634_CR11","doi-asserted-by":"publisher","unstructured":"Nota NM, Wiepjes CM, de Blok CJM, Gooren LJG, Kreukels BPC, den Heijer M. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation. 2019;139(11):1461\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038584","DOI":"10.1161\/CIRCULATIONAHA.118.038584"},{"issue":"3","key":"6634_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-018-9454-3","volume":"19","author":"MS Irwig","year":"2018","unstructured":"Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018;19(3):243\u201351. https:\/\/doi.org\/10.1007\/s11154-018-9454-3","journal-title":"Rev Endocr Metab Disord."},{"key":"6634_CR13","doi-asserted-by":"publisher","unstructured":"Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301\u201311. https:\/\/doi.org\/10.1016\/S2213-8587(16)00036-X","DOI":"10.1016\/S2213-8587(16)00036-X"},{"key":"6634_CR14","doi-asserted-by":"publisher","unstructured":"Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017;5(4):291\u2013300. https:\/\/doi.org\/10.1016\/S2213-8587(16)30319-9","DOI":"10.1016\/S2213-8587(16)30319-9"},{"key":"6634_CR15","doi-asserted-by":"publisher","unstructured":"van Velzen DM, Paldino A, Klaver M, et al. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. J Clin Endocrinol Metab. 2019;104(6):1937\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02138","DOI":"10.1210\/jc.2018-02138"},{"key":"6634_CR16","doi-asserted-by":"publisher","unstructured":"Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;72(1):1\u201310. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03632.x","DOI":"10.1111\/j.1365-2265.2009.03632.x"},{"key":"6634_CR17","doi-asserted-by":"publisher","unstructured":"Klaver M, Dekker M, de Mutsert R, Twisk JWR, den Heijer M. Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. Andrologia. 2017;49(5). https:\/\/doi.org\/10.1111\/and.12660","DOI":"10.1111\/and.12660"},{"key":"6634_CR18","doi-asserted-by":"publisher","unstructured":"Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471\u20138. https:\/\/doi.org\/10.1530\/eje-13-0493","DOI":"10.1530\/eje-13-0493"},{"key":"6634_CR19","doi-asserted-by":"publisher","unstructured":"Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric\/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869\u2013903. https:\/\/doi.org\/10.1210\/jc.2017-01658","DOI":"10.1210\/jc.2017-01658"},{"key":"6634_CR20","unstructured":"UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco, Guidelines for the Primary and Gender-Affiring Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. https:\/\/transcare.ucsf.edu\/guidelines. Accessed 6\/17\/2020."},{"key":"6634_CR21","doi-asserted-by":"publisher","unstructured":"Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. JBMR Plus. 2019;3(9):e10192. https:\/\/doi.org\/10.1002\/jbm4.10192","DOI":"10.1002\/jbm4.10192"},{"key":"6634_CR22","doi-asserted-by":"publisher","unstructured":"Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11\u20135. https:\/\/doi.org\/10.1016\/j.steroids.2014.12.010","DOI":"10.1016\/j.steroids.2014.12.010"},{"key":"6634_CR23","doi-asserted-by":"publisher","unstructured":"Rothman MS, Iwamoto SJ. Bone Health in the Transgender Population. Clin Rev Bone Miner Metab. 2019;17(2):77\u201385. https:\/\/doi.org\/10.1007\/s12018-019-09261-3","DOI":"10.1007\/s12018-019-09261-3"},{"key":"6634_CR24","doi-asserted-by":"publisher","unstructured":"Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013;54(1):92-7. https:\/\/doi.org\/10.1016\/j.bone.2013.01.039","DOI":"10.1016\/j.bone.2013.01.039"},{"key":"6634_CR25","doi-asserted-by":"publisher","unstructured":"Fighera TM, da Silva E, Lindenau JD, Spritzer PM. Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen. Clin Endocrinol (Oxf). 2018;88(6):856\u201362. https:\/\/doi.org\/10.1111\/cen.13607","DOI":"10.1111\/cen.13607"},{"key":"6634_CR26","doi-asserted-by":"publisher","unstructured":"Wiepjes CM, de Jongh RT, de Blok CJ, et al. Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen. J Bone Miner Res. 2019;34(3):447\u201354. https:\/\/doi.org\/10.1002\/jbmr.3612","DOI":"10.1002\/jbmr.3612"},{"key":"6634_CR27","doi-asserted-by":"publisher","unstructured":"Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017;102(11):3904-13. https:\/\/doi.org\/10.1210\/jc.2017-01642","DOI":"10.1210\/jc.2017-01642"},{"key":"6634_CR28","doi-asserted-by":"publisher","unstructured":"Wiepjes CM, de Blok CJ, Staphorsius AS, et al. Fracture Risk in Trans Women and Trans Men Using Long-Term Gender-Affirming Hormonal Treatment: A Nationwide Cohort Study. J Bone Miner Res. 2020;35(1):64\u201370. https:\/\/doi.org\/10.1002\/jbmr.3862","DOI":"10.1002\/jbmr.3862"},{"key":"6634_CR29","doi-asserted-by":"publisher","unstructured":"Panagiotakopoulos L. Transgender medicine - puberty suppression. Rev Endocr Metab Disord. 2018;19(3):221\u20135. https:\/\/doi.org\/10.1007\/s11154-018-9457-0","DOI":"10.1007\/s11154-018-9457-0"},{"issue":"4","key":"6634_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jocd.2019.07.004","volume":"22","author":"HN Rosen","year":"2019","unstructured":"Rosen HN, Hamnvik OR, Jaisamrarn U, et al. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position. J Clin Densitom. 2019;22(4):544\u201353. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.004","journal-title":"J Clin Densitom."},{"issue":"12","key":"6634_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/1471-0528.15258","volume":"125","author":"R Joint","year":"2018","unstructured":"Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG. 2018;125(12):1505\u201312. https:\/\/doi.org\/10.1111\/1471-0528.15258","journal-title":"BJOG."},{"issue":"12","key":"6634_CR32","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1111\/jsm.12319","volume":"10","author":"LJ Gooren","year":"2013","unstructured":"Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013;10(12):3129\u201334. https:\/\/doi.org\/10.1111\/jsm.12319","journal-title":"J Sex Med."},{"key":"6634_CR33","doi-asserted-by":"publisher","first-page":"l1652","DOI":"10.1136\/bmj.l1652","volume":"365","author":"CJM de Blok","year":"2019","unstructured":"de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019;365:l1652. https:\/\/doi.org\/10.1136\/bmj.l1652","journal-title":"BMJ."},{"issue":"1","key":"6634_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10549-014-3213-2","volume":"149","author":"GR Brown","year":"2015","unstructured":"Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat. 2015;149(1):191\u20138. https:\/\/doi.org\/10.1007\/s10549-014-3213-2","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"6634_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1369\/jhc.6A6928.2006","volume":"54","author":"MH Slagter","year":"2006","unstructured":"Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem. 2006;54(8):905\u201310. https:\/\/doi.org\/10.1369\/jhc.6A6928.2006","journal-title":"J Histochem Cytochem."},{"issue":"3","key":"6634_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0031-1281493","volume":"25","author":"SJ Monstrey","year":"2011","unstructured":"Monstrey SJ, Ceulemans P, Hoebeke P. Sex Reassignment Surgery in the Female-to-Male Transsexual. Semin Plast Surg. 2011;25(3):229\u201344. https:\/\/doi.org\/10.1055\/s-0031-1281493","journal-title":"Semin Plast Surg."},{"key":"6634_CR37","doi-asserted-by":"publisher","unstructured":"Committee on Health Care for Underserved W. Committee Opinion no. 512: health care for transgender individuals. Obstet Gynecol. 2011;118(6):1454\u20138. https:\/\/doi.org\/10.1097\/AOG.0b013e31823ed1c1","DOI":"10.1097\/AOG.0b013e31823ed1c1"},{"issue":"5","key":"6634_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2214\/AJR.13.10810","volume":"202","author":"J Phillips","year":"2014","unstructured":"Phillips J, Fein-Zachary VJ, Mehta TS, Littlehale N, Venkataraman S, Slanetz PJ. Breast imaging in the transgender patient. AJR Am J Roentgenol. 2014;202(5):1149\u201356. https:\/\/doi.org\/10.2214\/AJR.13.10810","journal-title":"AJR Am J Roentgenol."},{"issue":"4","key":"6634_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369\u201380. https:\/\/doi.org\/10.1001\/jama.2020.9482","journal-title":"JAMA."},{"key":"6634_CR40","doi-asserted-by":"publisher","unstructured":"Eismann J, Heng YJ, Fleischmann-Rose K, et al. Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. Clin Breast Cancer. 2018. https:\/\/doi.org\/10.1016\/j.clbc.2018.11.007","DOI":"10.1016\/j.clbc.2018.11.007"},{"issue":"5","key":"6634_CR41","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/j.clbc.2016.08.003","volume":"17","author":"S Pivo","year":"2017","unstructured":"Pivo S, Montes J, Schwartz S, et al. Breast Cancer Risk Assessment and Screening in Transgender Patients. Clin Breast Cancer. 2017;17(5):e225\u2013e7. https:\/\/doi.org\/10.1016\/j.clbc.2016.08.003","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"6634_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jama.291.4.442","volume":"291","author":"DL Miglioretti","year":"2004","unstructured":"Miglioretti DL, Rutter CM, Geller BM, et al. Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA. 2004;291(4):442\u201350. https:\/\/doi.org\/10.1001\/jama.291.4.442","journal-title":"JAMA."},{"issue":"4","key":"6634_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s13244-018-0636-z","volume":"9","author":"A Evans","year":"2018","unstructured":"Evans A, Trimboli RM, Athanasiou A, et al. Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging. 2018;9(4):449\u201361. https:\/\/doi.org\/10.1007\/s13244-018-0636-z","journal-title":"Insights Imaging."},{"key":"6634_CR44","doi-asserted-by":"publisher","unstructured":"Committee on Practice B-G. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;128(4):e111-30. https:\/\/doi.org\/10.1097\/AOG.0000000000001708","DOI":"10.1097\/AOG.0000000000001708"},{"issue":"1","key":"6634_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","journal-title":"J Pathol."},{"issue":"2","key":"6634_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2014.12.022","journal-title":"Gynecol Oncol."},{"issue":"3","key":"6634_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190172","volume":"13","author":"SL Reisner","year":"2018","unstructured":"Reisner SL, Deutsch MB, Peitzmeier SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One. 2018;13(3):e0190172. https:\/\/doi.org\/10.1371\/journal.pone.0190172","journal-title":"PLoS One."},{"issue":"12","key":"6634_CR48","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s11606-015-3462-8","volume":"30","author":"J Potter","year":"2015","unstructured":"Potter J, Peitzmeier SM, Bernstein I, et al. Cervical Cancer Screening for Patients on the Female-to-Male Spectrum: a Narrative Review and Guide for Clinicians. J Gen Intern Med. 2015;30(12):1857\u201364. https:\/\/doi.org\/10.1007\/s11606-015-3462-8","journal-title":"J Gen Intern Med."},{"issue":"3","key":"6634_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cyt.12525","volume":"29","author":"BD Adkins","year":"2018","unstructured":"Adkins BD, Barlow AB, Jack A, et al. Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: Challenges in detecting dysplasia. Cytopathology. 2018;29(3):281\u20137. https:\/\/doi.org\/10.1111\/cyt.12525","journal-title":"Cytopathology."},{"key":"6634_CR50","unstructured":"Surveillance, Epidemiology, and End Results Program (SEER), Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. ."},{"key":"6634_CR51","doi-asserted-by":"publisher","unstructured":"Kensler KH, Pernar CH, Mahal BA, et al. Racial\/ethnic variation in PSA testing and prostate cancer incidence following the 2012 U.S.P.S.T.F. recommendation. J Natl Cancer Inst. 2020. https:\/\/doi.org\/10.1093\/jnci\/djaa171","DOI":"10.1093\/jnci\/djaa171"},{"issue":"4","key":"6634_CR52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0022-5347(01)65584-8","volume":"156","author":"P van Kesteren","year":"1996","unstructured":"van Kesteren P, Meinhardt W, van der Valk P, Geldof A, Megens J, Gooren L. Effects of estrogens only on the prostates of aging men. J Urol. 1996;156(4):1349\u201353.","journal-title":"J Urol."},{"key":"6634_CR53","doi-asserted-by":"publisher","unstructured":"Ingham MD, Lee RJ, MacDermed D, Olumi AF. Prostate cancer in transgender women. Urol Oncol. 2018. https:\/\/doi.org\/10.1016\/j.urolonc.2018.09.011","DOI":"10.1016\/j.urolonc.2018.09.011"},{"issue":"8","key":"6634_CR54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.annepidem.2017.07.007","volume":"27","author":"MJ Silverberg","year":"2017","unstructured":"Silverberg MJ, Nash R, Becerra-Culqui TA, et al. Cohort study of cancer risk among insured transgender people. Ann Epidemiol. 2017;27(8):499\u2013501. https:\/\/doi.org\/10.1016\/j.annepidem.2017.07.007","journal-title":"Ann Epidemiol."},{"issue":"8","key":"6634_CR55","first-page":"683","volume":"92","author":"E Mulhem","year":"2015","unstructured":"Mulhem E, Fulbright N, Duncan N. Prostate Cancer Screening. Am Fam Physician. 2015;92(8):683-8.","journal-title":"Am Fam Physician."},{"issue":"6","key":"6634_CR56","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/aogs.12618","volume":"94","author":"HW Trum","year":"2015","unstructured":"Trum HW, Hoebeke P, Gooren LJ. Sex reassignment of transsexual people from a gynecologist's and urologist's perspective. Acta Obstet Gynecol Scand. 2015;94(6):563\u20137. https:\/\/doi.org\/10.1111\/aogs.12618","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"1","key":"6634_CR57","first-page":"35","volume":"2","author":"S Weyers","year":"2010","unstructured":"Weyers S, De Sutter P, Hoebeke S, et al. Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views Vis Obgyn. 2010;2(1):35\u201354.","journal-title":"Facts Views Vis Obgyn."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-06634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-06634-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-06634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T01:05:38Z","timestamp":1644023138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-06634-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6634"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-06634-7","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MSR completed a one-time consulting project for AbbVie. SJI, FG and MSI declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}